PAVmed PAVM Estimates

NASDAQ PAVM
$4.86 +0.14 (+2.97%)
As of: Sep 9, 2026 · 11:09 AM EDT
Analyst Estimates

PAVmed Inc. Revenue Estimates

Periods 18
Next Period Q3 26
Consensus 25,815.00

Analysts expect PAVmed Inc. to report revenue of 25,815.00 for Q3 26, against a range of 24,660.71 to 26,969.29. The most recent reported quarter, Q2 26, came in at 33,000.00, a 33.5% miss against the 49,642.08 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 996,000.0010,000.008,000.006,000.005,000.0052,000.0022,000.0033,000.00--------
High Estimate 1.09 M20,505.139,936.6011,367.4413,498.820.0085,075.8052,755.5326,969.29141,572.4588,406.04117,058.4077,280.13368,543.25261,503.85428,104.52
Low Estimate 970,963.3618,141.879,178.109,300.7612,242.940.0071,742.0446,528.6324,660.71130,806.1576,163.08102,567.4866,543.29316,884.61234,776.19390,844.00
Consensus Estimate 1.03 M19,323.509,557.3510,334.1012,870.880.0078,408.9249,642.0825,815.00136,189.3082,284.56109,812.9471,911.71342,713.93248,140.02409,474.26
Analyst Estimates

PAVmed Inc. Earnings Per Share (EPS) Estimates

Periods 18
Next Period Q3 26
Consensus -0.55

Analysts expect PAVmed Inc. to report earnings per share of -0.55 for Q3 26, against a range of -0.59 to -0.51. The most recent reported quarter, Q2 26, came in at -0.87, a 81.3% miss against the -0.48 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 193.103.9710.20-22.20-8.70-2.05-4.42-0.87--------
High Estimate 65.68-3.19-10.08-3.41-4.87-4.78-0.64-0.46-0.51-0.54-0.47-0.51-15.98-30.90-15.32-3.94
Low Estimate 57.10-3.75-12.20-4.11-5.87-5.46-0.68-0.50-0.59-0.62-0.49-0.55-19.10-35.60-18.20-4.48
Consensus Estimate 61.39-3.47-11.14-3.76-5.37-5.12-0.66-0.48-0.55-0.58-0.48-0.53-17.54-33.25-16.76-4.21